Clinical features and mutation analysis of class 1/2/3 BRAF mutation colorectal cancerYingying Huang, Guoju Wu, Yunbo Zhao et al.|Chinese Clinical Oncology|2024Cited by 5
Partial response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic BRAF V600EMT colon cancer patient with acquired C-MET amplification and TPM4-ALK fusion: a case reportYingying Huang, Zhongkang Li, Shuai Zhang et al.|AME Case Reports|2024Cited by 2
Response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic BRAF V600E MT colon cancer patients with acquired C-MET amplification and TPM4- ALK fusion: case report and review of literatureShuai Zhang, Yingying Huang, Xueqing Hu et al.|Research Square|2022Cited by 0
Define a good prognosis of RNF43 codon 659-mutated and concomitant genomic signatures in CRC: an analysis of the cBioPortal databaseFeng Wang, Yingying Huang, Yunbo Zhao et al.|Frontiers in Oncology|2025Cited by 0